No profile data available.
Janux Therapeutics, Inc. (JANX) is a healthcare company in the additional cancer treatment drugs industry, based in San Diego, United States, with about 113 full-time employees.
It reported revenue of $10.59 million for fiscal year 2024, up 31.0% from fiscal year 2023, and net income of -$68.99 million. In Q3 2025 (the quarter ended September 30, 2025) revenue was $10.00 million, up 2177.9% from a year before. Its market capitalization was $1.12 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2024; market data as of October 9, 2026.
, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer.
Janux Therapeutics reported $10.59 million in revenue for fiscal year 2024, up 31.0% from $8.08 million in fiscal year 2023. In Q3 2025 revenue was $10.00 million.
$1.12 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Oric Pharmaceuticals, Inc. (ORIC), Bicara Therapeutics Inc. (BCAX), Immatics N.v. (IMTX), Adlai Nortye Ltd. (ANL).